Zoetis Inc Stock Price, News & Analysis

Zoetis (NYSE:ZTS) declared a $0.50 per share dividend for the fourth quarter of 2025. The dividend will be paid on December 2, 2025 to holders of record as of the close of business on October 31, 2025.

This provides a scheduled cash return to shareholders for Q4 2025 and specifies the payment and record dates.

Zoetis (NYSE:ZTS) has received conditional FDA approval for Dectomax®-CA1 Injectable, making it the first and only parasite control product approved for preventing and treating New World screwworm (Cochliomyia hominivorax) myiasis in cattle. The approval covers beef cattle, female dairy cattle under 20 months, pregnant beef cows, newborn calves, and bulls.

The treatment provides 21 days of protection against reinfestation. This development is significant as New World screwworm poses a substantial threat to livestock health, with potential economic impacts estimated in the billions of dollars. The product will be available in 250ml and 500ml bottles in the first half of 2026.

Zoetis (NYSE:ZTS), a leading animal health company, has announced it will host a webcast and conference call to discuss its third quarter 2025 financial results on Tuesday, November 4, 2025, at 8:30 a.m. ET.

CEO Kristin Peck and CFO Wetteny Joseph will present the quarterly results and participate in a Q&A session with financial analysts. The webcast will be accessible through Zoetis's investor relations website, with pre-registration now open. A replay will be available after the event.

Zoetis (NYSE:ZTS) has received a positive opinion from the European Medicines Agency's CVMP for Portela® (relfovetmab), a groundbreaking monoclonal antibody therapy for cats with osteoarthritis pain. If approved, Portela will be the first long-acting anti-NGF mAb therapy providing three months of pain relief with a single injection.

The therapy demonstrated strong efficacy in clinical trials and was well-tolerated, including in cats with kidney disease. With up to 40% of cats showing clinical signs of osteoarthritis but only 18% receiving diagnosis, Portela addresses a significant unmet medical need. The European Commission's decision is expected in Q4 2025, with commercial availability planned for 2026.

Zoetis (NYSE:ZTS), a leading animal health company, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's presentation is scheduled for Monday, September 8 at 1:05 p.m. ET.

Investors and interested parties can access the presentation through a live audio webcast on the company's investor relations website. A replay of the presentation will be made available after the event.

Zoetis (NYSE:ZTS) has announced the pricing of a $1.85 billion senior notes offering, comprising of $850 million in 4.150% notes due 2028 and $1 billion in 5.000% notes due 2035. The company plans to use the proceeds primarily to repay existing debt, including $750 million of 4.500% notes and $600 million of 5.400% notes, both due in 2025.

The offering is expected to close on August 18, 2025, with major financial institutions including Barclays, BofA Securities, Citigroup, J.P. Morgan, and MUFG Securities Americas serving as joint book-running managers.

Zoetis (NYSE:ZTS) reported strong Q2 2025 results with revenue reaching $2.5 billion, up 4% year-over-year, and net income of $718 million ($1.61 per diluted share), increasing 15%. The company achieved 8% organic operational revenue growth and 10% organic operational growth in adjusted net income.

Following robust first-half performance, Zoetis raised its full year 2025 guidance, projecting revenue between $9.450-$9.600 billion with organic operational growth of 6.5-8.0%. The company increased its adjusted EPS guidance to $6.30-$6.40.

U.S. segment revenue reached $1.4 billion, up 4%, driven by companion animal products growth of 9%, while International segment revenue grew 3% to $1.1 billion. Key growth drivers included Simparica Trio, dermatology portfolio, and expansion of product approvals across markets.

Zoetis (NYSE:ZTS) announced it will host a webcast and conference call on Tuesday, August 5, 2025, at 8:30 a.m. ET to discuss its second quarter 2025 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and take questions from financial analysts. The webcast will be accessible through the company's investor relations website, with pre-registration now open. A replay will be available on the same day.

Zoetis (ZTS) has released its 2024 Sustainability Progress Update, highlighting significant achievements across its Communities, Animals, and Planet initiatives. The company reported a 23% increase in employee volunteer hours, reaching 20,404 hours. The Zoetis Foundation distributed $11.3 million in grants, including $3.5 million for veterinary student scholarships. Key environmental achievements include sourcing 80.6% of global electricity from renewable sources and reducing Scope 1 and 2 emissions by 26.7% from 2023. The company launched strategic partnerships with Danone for sustainable dairy breeding and AgNext for cattle industry sustainability. Zoetis also expanded its African Livestock initiative, treating 16.7 million cows and 354.9 million chickens, while maintaining a strong 86% employee engagement rate. The company implemented sustainable packaging solutions and installed new solar arrays, demonstrating its commitment to environmental stewardship.